Human immunodeficiency virus and tuberculosis coinfection in children: Challenges in diagnosis and treatment

Pediatric Infectious Disease Journal

Volumn 29, Issue 10, 2010, Pages

  Verhagen, Lilly M ^a   Warris, Adilia ^a   Van Soolingen, Dick ^b   De Groot, Ronald ^a   Hermans, Peter W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

children; diagnosis; disease transmission; drug interactions; epidemiology; HIV; immune reconstitution inflammatory syndrome; therapy; tuberculosis; tuberculosis vaccines

Indexed keywords

AMIKACIN; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; BCG VACCINE; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; DIDANOSINE; EFAVIRENZ; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LINEZOLID; LOPINAVIR; METRONIDAZOLE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; RITONAVIR;

ASPIRATION BIOPSY; BACTERIUM CULTURE; CHEMOPROPHYLAXIS; CHILD; DISEASE TRANSMISSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MIXED INFECTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; THORAX RADIOGRAPHY; TUBERCULOSIS; VACCINATION;

EID: 77957266889     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181ee23ae     Document Type: Article

References (99)

1. World Health Organization. Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. Geneva, Switzerland: World Health Organization; 2006.
2. Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res. 1976;19: 1-63.
3. Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect. 1997;119:183-201. (Pubitemid 27474799)
4. Djoba Siawaya JF, Ruhwald M, Eugen-Olsen J, et al. Correlates for disease progression and prognosis during concurrent HIV/TB infection. Int J Infect Dis. 2007;11:289-299. (Pubitemid 46994763)
5. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med. 1992;326:231-235.
6. Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis. 2005;191:150-158. (Pubitemid 40096371)
7. Palme IB, Gudetta B, Bruchfeld J, et al. Impact of human immunodeficiency virus 1 infection on clinical presentation, treatment outcome and survival in a cohort of Ethiopian children with tuberculosis. Pediatr Infect Dis J. 2002;21:1053-1061. (Pubitemid 35334515)
8. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS. 2009;4:325-333.
9. Schaaf HS, Marais BJ, Whitelaw A, et al. Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases. BMC Infect Dis. 2007;7:140. (Pubitemid 351211016)
10. Madhi SA, Huebner RE, Doedens L, et al. HIV-1 co-infection in children hospitalised with tuberculosis in South Africa. Int J Tuberc Lung Dis. 2000;4:448-454. (Pubitemid 30256848)
11. Jeena PM, Pillay P, Pillay T, et al. Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa. Int J Tuberc Lung Dis. 2002;6:672-678. (Pubitemid 34832146)
12. Daniel OJ, Ogunfowora OB, Oladapo OT. HIV sero-prevalence among children diagnosed with TB in Nigeria. Trop Doct. 2007;37:268-269.
13. Coovadia HM, Jeena P, Wilkinson D. Childhood human immunodeficiency virus and tuberculosis co-infections: reconciling conflicting data. Int J Tuberc Lung Dis. 1998;2:844-851. (Pubitemid 28462001)
14. Elenga N, Kouakoussui KA, Bonard D, et al. Diagnosed tuberculosis during the follow-up of a cohort of human immunodeficiency virus-infected children in Abidjan, Cote d'Ivoire: ANRS 1278 study. Pediatr Infect Dis J. 2005;24:1077-1082. (Pubitemid 43011064)
15. Van Rie A, Beyers N, Gie RP, et al. Childhood tuberculosis in an urban population in South Africa: burden and risk factor. Arch Dis Child. 1999;80:433-437. (Pubitemid 29220178)
16. Working Group on Mother-to-Child Transmission of HIV. Rates of motherto-child transmission of HIV-1 in Africa, America and Europe: results from 13 perinatal studies. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 8:506-510.
17. Hesseling AC, Cotton MF, Jennings T, et al. High incidence of tuberculosis among HIV-infected infants: evidence from a South African populationbased study highlights the need for improved tuberculosis control strategies. Clin Infect Dis. 2009;48:108-114.
18. Pillay T, Khan M, Moodley J, et al. The increasing burden of tuberculosis in pregnant women, newborns and infants under 6 months of age in Durban, KwaZulu-Natal. S Afr Med J. 2001;91:983-987. (Pubitemid 34041123)
19. Pillay T, Sturm AW, Khan M, et al. Vertical transmission of Mycobacterium tuberculosis in KwaZulu Natal: impact of HIV-1 co-infection. Int J Tuberc Lung Dis. 2004;8:59-69. (Pubitemid 38120707)
20. Marais BJ, Wright CA, Schaaf HS, et al. Tuberculous lymphadenitis as a cause of persistent cervical lymphadenopathy in children from a tuberculosis-endemic area. Pediatr Infect Dis J. 2006;25:142-146.
21. Wright CA, van der Burg M, Geiger D, et al. Diagnosing mycobacterial lymphadenitis in children using fine needle aspiration biopsy: cytomorphology, ZN staining and autofluorescence-making more of less. Diagn Cytopathol. 2008;36:245-251. (Pubitemid 351458183)
22. Vargas D, Garcia L, Gilman RH, et al. Diagnosis of sputum-scarce HIV-associated pulmonary tuberculosis in Lima, Peru. Lancet. 2005;365: 150-152. (Pubitemid 40091805)
23. Chow F, Espiritu N, Gilman RH, et al. La cuerda dulce-a tolerability and acceptability study of a novel approach to specimen collection for diagnosis of paediatric pulmonary tuberculosis. BMC Infect Dis. 2006;6:67. (Pubitemid 43983123)
24. Zar HJ, Hanslo D, Apolles P, et al. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet. 2005;365:130-134. (Pubitemid 40091802)
25. Berggren Palme I, Gudetta B, Bruchfeld J, et al. Detection of Mycobacterium tuberculosis in gastric aspirate and sputum collected from Ethiopian HIV-positive and HIV-negative children in a mixed in-and outpatient setting. Acta Paediatr. 2004;93:311-315. (Pubitemid 38316551)
26. Kiwanuka J, Graham SM, Coulter JB, et al. Diagnosis of pulmonary tuberculosis in children in an HIV-endemic area, Malawi. Ann Trop Paediatr. 2001;21:5-14. (Pubitemid 32243659)
27. Marais BJ, Gie RP, Hesseling AC, et al. A refined symptom-based approach to diagnose pulmonary tuberculosis in children. Pediatrics. 2006;118: e1350-e1359.
28. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis. 1993;17:968-975.
29. Madhi SA, Gray GE, Huebner RE, et al. Correlation between CD4 lymphocyte counts, concurrent antigen skin test and tuberculin skin test reactivity in human immunodeficiency virus type 1-infected and-uninfected children with tuberculosis. Pediatr Infect Dis J. 1999;18:800-805.
30. Connell TG, Ritz N, Paxton GA, et al. A three-way comparison of tuberculin skin testing, QuantiFERON-TB gold and T-SPOT. TB in children. PLoS One. 2008;3:e2624.
31. Connell TG, Curtis N, Ranganathan SC, et al. Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children. Thorax. 2006;61:616-620. (Pubitemid 44035143)
32. Lewinsohn DA, Lobato N, Jereb JA. Interferon-GAMMA release assays: new diagnostic tests for Mycobacterium tuberculosis infection, and their use in children. Curr Opin Pediatr. 2010;22:71-76.
33. Higuchi K, Kondo S, Wada M, et al. Contact investigation in a primary school using a whole blood interferon-gamma assay. J Infect. 2009;58:352-357.
34. Liebeschuetz S, Bamber S, Ewer K, et al. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet. 2004;3:2196-2203. (Pubitemid 40018449)
35. Davies MA, Connell T, Johannisen C, et al. Detection of tuberculosis in HIV-infected children using an enzyme-linked immunospot assay. AIDS. 2009;23:961-969.
36. Ferrara G, Losi M, D'Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet. 2006;367:1328-1334.
37. Haustein T, Ridout DA, Hartley JC, et al. The likelihood of an indeterminate test result from a whole-blood interferon-gamma release assay for the diagnosis of Mycobacterium tuberculosis infection in children correlates with age and immune status. Pediatr Infect Dis J. 2009;28:669-673.
38. Mutsvangwa J, Millington KA, Chaka K, et al. Identifying recent Mycobacterium tuberculosis transmission in the setting of high HIV and TB burden. Thorax. 2010;65:315-320.
39. Schaaf HS, Krook S, Hollemans DW, et al. Recurrent culture-confirmed tuberculosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2005;24:685-691. (Pubitemid 41140950)
40. Driver C, Munsiff S, Li J, et al. Relapse in persons treated for drugsusceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis. 2001;33:1762-1769. (Pubitemid 33044545)
41. Perriens JH, St Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med. 1995;332:779-784.
42. Lopez-Cortes LF, Marin-Niebla A, Lopez-Cortes LE, et al. Influence of treatment and immunological recovery on tuberculosis relapses in HIVinfected patients. Int J Tuberc Lung Dis. 2005;9:1385-1390. (Pubitemid 43265150)
43. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359:2059-2064. (Pubitemid 34680968)
44. Lawn SD, Myer L, Bekker LG, et al. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006;20: 1605-1612. (Pubitemid 44162402)
45. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS. 2000;14:1985-1991.
46. Jones JL, Hanson DL, Dworkin MS, et al; The Adult/Adolescent Spectrum of HIV Disease Group. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. Int J Tuberc Lung Dis. 2000;4:1026-1031.
47. Girardi E, Palmieri F, Cingolani A, et al. Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26:326-331. (Pubitemid 32435996)
48. Hung CC, Hsiao CF, Chen MY, et al. Improved survival of persons with human immunodeficiency virus type 1 infection in the era of highly active antiretroviral therapy in Taiwan. Jpn J Infect Dis. 2006;59:222-228. (Pubitemid 44304656)
49. Hung CC, Chen MY, Hsiao CF, et al. Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS. 2003;17:2615-2622. (Pubitemid 38402339)
50. Makombe SD, Harries AD, Yu JK, et al. Outcomes of tuberculosis patients who start antiretroviral therapy under routine programme conditions in Malawi. Int J Tuberc Lung Dis. 2007;11:412-416. (Pubitemid 46595771)
51. Dheda K, Lampe FC, Johnson MA, et al. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis. 2004;190:1670-1676. (Pubitemid 39411018)
52. Martinson N, Moultrieh H, Barry G, et al. Incidence of tuberculosis in HIV-infected children: the influence of HAART. Paper presented at: 13th Conference of Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO.
53. Walters E, Cotton MF, Rabie H, et al. Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on antiretroviral therapy. BMC Pediatr. 2008;8:1. (Pubitemid 351285302)
54. Kouakoussui A, Fassinou P, Anaky MF, et al. Respiratory manifestations in HIV-infected children pre-and post-HAART in Abidjan, the Ivory Coast. Paediatr Respir Rev. 2004;5:311-315. (Pubitemid 39462675)
55. World Health Organization. Antiretroviral Therapy in HIV Infection in Infants and Children in Resource-Limited Settings: Towards Universal Access. Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2006.
56. American Thoracic Society; CDC; Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep. 2003;52:1-77.
57. CDC. Managing drug interactions in the treatment of HIV-related Tuberculosis; Avalaible at: http://www.cdc.gov/tb/TB-HIV-Drugs/default.htm. Accessed September 29, 2009.
58. Ren Y, Nuttall JJ, Eley BS, et al. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2009;50:439-443. (Pubitemid 351442016)
59. Barlow-Mosha L, Musoke P, Parsons T, et al. Nevirapine Concentrations in HIV-infected Ugandan children on adult fixed-dose combination tablet ART, with and without rifampicin-based treatment for Active M. tuberculosis infection. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Canada.
60. Oudijk JM, Mcilleron H, Mulenga V, et al. Pharmacokinetics of nevirapine in young children during combined ART and rifampicin-containing antituberculosis treatment. Paper presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July19-22, 2009; Cape Town, South Africa.
61. Prasitsuebsai W, Cressey T, Capparelli E, et al. Pharmacokinetics of nevirapine when Co-administered with rifampin in HIV-infected Thai children with TB. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 9-11, 2009; Montreal, Canada.
62. Bobat R, Kiepiela P, Kindra G, et al. Resistance in ART-naïve paediatric subjects with chronic HIV-1 infection: experiences from a pilot study. Paper presented at: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia.
63. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850-1861.
64. Meyers T, Eley B; National department of health, South Africa. Guidelines for the Management of HIV-Infected Children. 1st ed. Pinetown, South Africa: Jacana Publishers; 2005.
65. Reitz C, Coovadia A, Meyers T, et al. Virologic response to protease inhibitorbased ART among children younger than 2 years of age co-treated for TB in South Africa. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 9-11, 2009; Montreal, Canada.
66. McIlleron H, Ren Y, Nuttall J, et al. Double-dose lopinavir/ritonavir provides insufficient lopinavir exposure in children receiving rifampicin-based anti-TB treatment. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 9-11, 2009; Montreal, Canada.
67. Ren Y, Nuttall JJ, Egbers C, et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2008;47:566-569. (Pubitemid 351442016)
68. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev. 2007:CD005159. (Pubitemid 351805361)
69. Blake MJ, Abdel-Rahman SM, Jacobs RF, et al. Pharmacokinetics of rifapentine in children. Pediatr Infect Dis J. 2006;25:405-409. (Pubitemid 43755093)
70. Marshall JD, Abdel-Rahman S, Johnson K, et al. Rifapentine pharmacokinetics in adolescents. Pediatr Infect Dis J. 1999;18:882-888. (Pubitemid 29487508)
71. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis. 2005;5:361-373.
72. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resourcelimited settings. Lancet Infect Dis. 2008;8:516-523. (Pubitemid 352005824)
73. Boulware DR, Callens S, Pahwa S. Pediatric HIV immune reconstitution inflammatory syndrome. Curr Opin HIV AIDS. 2008;3:461-467.
74. Colebunders R, John L, Huyst V, et al. Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int J Tuberc Lung Dis. 2006;10:946-953. (Pubitemid 44378968)
75. Puthanakit T, Oberdorfer P, Akarathum N, et al. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected Thai children. Pediatr Infect Dis J. 2006;25:53-58. (Pubitemid 43361477)
76. Wang ME, Castillo ME, Montano SM, et al. Immune reconstitution inflammatory syndrome in human immunodeficiency virus-infected children in Peru. Pediatr Infect Dis J. 2009;28:900-903.
77. Leone S, Nicastri E, Giglio S, et al. Immune reconstitution inflammatory syndrome associated with Mycobacterium tuberculosis infection: a systematic review. Int J Infect Dis. 2010;14:e283-e291.
78. Bakeera-Kitaka S, Dhabangi A, Namulema E. Immune reconstitution inflammatory syndrome and post-antiretroviral tuberculosis among HIV-infected Ugandan children. Paper presented at: 45th Infectious Diseases Society of America Annual Conference; October 4-7, 2007; San Diego, CA.
79. Meintjes G, Wilkinson R, Morroni C, et al. Randomized placebo-controlled trial of prednisone for the TB immune reconstitution inflammatory syndrome. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 9-11, 2009; Montreal, Canada.
80. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-1580. (Pubitemid 44780738)
81. Van Deun A, Martin A, Palomino JC. Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis. 2010;14: 131-140.
82. Glynn JR, Whiteley J, Bifani PJ, et al. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis. 2002;8:843-849.
83. Marais BJ, Victor TC, Hesseling AC, et al. Beijing and Haarlem genotypes are overrepresented among children with drug-resistant tuberculosis in the Western Cape Province of South Africa. J Clin Microbiol. 2006;44:3539-3543.
84. European Concerted Action on New Generation Genetic Marers; Techniques for the Epidemiology and Control of Tuberculosis. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg Infect Dis. 2006;12:736-743.
85. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva, Switzerland: World Health Organization; 2008.
86. Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis. 2007;196(suppl 1):S86-S107. (Pubitemid 47206088)
87. Arrive E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol. 2007;36: 1009-1021. (Pubitemid 350018545)
88. Bulletin of the National Institutes of Health. Ritonavir-Boosted Lopinavir Proves Superior to Nevirapine in HIV-Infected Infants Who Received Single-Dose Nevirapine at Birth; May 6, 2009. Available at: http://www3.niaid. nih.gov/news/newsreleases/2009/P1060.htm. Accessed October 9, 2009.
89. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367:1173-1180.
90. Hesseling AC, Rabie H, Marais BJ, et al. Bacille Calmette-Guerin vaccineinduced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis. 2006;42:548-558. (Pubitemid 43202529)
91. Hesseling AC, Marais BJ, Gie RP, et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine. 2007; 25:14-18.
92. Fallo A, Torrado L, Sanches A, et al. Delayed complications of Bacille Calmette-Guerin (BCG) vaccination in HIV-infected children. Paper presented at: 3rd International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 24-27, 2005; Rio de Janeiro, Brazil.
93. World Health Organization. Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec. 2007;82:193-196. Available at: http://www.who.int/wer/2007/wer8221.pdf. Accessed March 1, 2009.
94. Hesseling AC, Cotton MF, Fordham von RC, et al. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis. 2008;12:1376-1379.
95. Zar HJ, Cotton MF, Strauss S, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ. 2007;334:136. (Pubitemid 46173957)
96. Madhi SA, Nachman S, Violari A, et al. Lack of efficacy of primary isoniazid (INH) prophylaxis in increasing tuberculosis (TB) free survival in HIV-infected (HIV) South African children. Paper presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting; October 25-28, 2008; Washington, DC.
97. Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;21:1441-1448. (Pubitemid 46988004)
98. Le Roux SM, Cotton MF, Golub JE, et al. Adherence to isoniazid prophylaxis among HIV-infected children: a randomized controlled trial comparing two dosing schedules. BMC Med. 2009;7:67.
99. Schaaf SH, Gie RP, Kennedy M, et al. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics. 2002;109:765-771. (Pubitemid 34493340)